

**Plasmodium falciparum, Strain IPC 4912**

**Catalog No. MRA-1241**

**Product Description:** *Plasmodium falciparum* (*P. falciparum*), strain IPC 4912 was isolated in 2011 from the blood of a human patient with malaria in Mondulkiri province, southeastern Cambodia. *P. falciparum*, strain IPC 4912 has shown resistance to artemisinin.

**Lot<sup>1</sup>: 64417019**

**Manufacturing Date: 22JUL2016**

TEST	SPECIFICATIONS	RESULTS
<b>Identification by Giemsa Stain Microscopy<sup>2</sup></b>	Blood-stage parasites present	Blood-stage parasites present
<b>Antimalarial Susceptibility Profile (<i>in vitro</i>)</b> Half-maximal Inhibitory Concentration (IC <sub>50</sub> ) by SYBR green I <sup>®</sup> drug sensitivity assay <sup>3</sup> Chloroquine Artemisinin Quinine Cycloguanil Pyrimethamine Sulfadoxine Ring-stage Survival Assay (RSA <sub>0-3h</sub> ) <sup>4</sup> Dihydroartemisin (DHA) <sup>5</sup>	Report results Report results Report results Report results Report results Report results Report results	63.0 ± 4.4 nM 4.1 ± 0.5 nM 349.7 ± 24.2 nM 351.1 ± 81.6 nM 26740 ± 4328.7 nM 226700 ± 47317 nM
<b>Genotypic Analysis</b> Sequencing of Merozoite Surface Protein 2 (MSP2) gene (~ 760 base pairs) MSP2 PCR amplicon analysis <sup>6</sup> Sequencing of kelch protein (K13-propeller) gene <sup>7</sup> (~ 1970 base pairs)	Consistent with <i>P. falciparum</i> ~ 600-900 base pair amplicon K13 I543T mutation present	Consistent with <i>P. falciparum</i> (Figure 1) ~ 900 base pair amplicon K13 I543T mutation present (Figure 2)
<b>Level of Parasitemia</b> Pre-freeze <sup>8</sup> Post-freeze <sup>9</sup>	Report results > 1%	4.47% 9.03%
<b>Viability (post-freeze)<sup>10</sup></b>	Growth in infected red blood cells	Growth in infected red blood cells (Figure 3)
<b>Sterility (21-day incubation)</b> Harpo's HTYE broth <sup>11</sup> , 37°C and 26°C, aerobic Tryptic Soy broth, 37°C and 26°C, aerobic Sabouraud Dextrose broth, 37°C and 26°C, aerobic DMEM with 10% FBS, 37°C, aerobic Sheep Blood agar, 37°C, aerobic Sheep Blood agar, 37°C, anaerobic Thioglycollate broth, 37°C, anaerobic	No growth No growth No growth No growth No growth No growth No growth	No growth No growth No growth No growth No growth No growth No growth
<b>Mycoplasma Contamination</b> DNA Detection by PCR	None detected	None detected

<sup>1</sup>MRA-1241 was produced by cultivation of MR-MRA-1241 lot 62401484 in fresh human erythrocytes suspended in RPMI 1640 medium, adjusted to contain 10% (v/v) heat-inactivated human serum (pooled Type A), 25 mM HEPES, 2 mM L-glutamine, 4 g/L D-glucose, 0.005 µg/mL hypoxanthine and 2.5 µg/mL gentamicin. The culture was incubated at 37°C in sealed flasks outgassed with blood-gas atmosphere (90% N<sub>2</sub>, 5% CO<sub>2</sub>, 5% O<sub>2</sub>) and monitored for parasitemia daily for 8 days. Every 1 to 3 days, uninfected, leukocyte filtered, Type O erythrocytes in complete culture medium were added dropwise to the culture to maintain 2% hematocrit.

<sup>2</sup>Blood-stage malaria parasites (rings, trophozoites, schizonts +/- gametocytes) were examined by microscopic Giemsa-stained blood smears of an *in vitro* human blood culture over 6 days.

<sup>3</sup>A SYBR Green I<sup>®</sup> anti-malarial drug sensitivity assay in 96-well plates was used to determine IC<sub>50</sub> values of an active (> 70% ring stage) parasite culture in the presence of each antimalarial drug [Hartwig, C. L., et al. "XI: I. SYBR Green I<sup>®</sup>-Based Parasite Growth Inhibition Assay for Measurement

- of Antimalarial Drug Susceptibility in *Plasmodium falciparum*." In *Methods in Malaria Research Sixth Edition*. (2013) Moll, K., et al. (Ed.), EVIMalaR, pp. 122-129. Available at: <https://www.beiresources.org/Publications/MethodsInMalariaResearch.aspx>].
- <sup>4</sup>A detailed RSA<sub>0-3h</sub> protocol is available on the Worldwide Antimalarial Resistance Network's website at <http://www.wwarn.org/tools-resources/procedures/ring-stage-survival-assays-rsa-evaluate-vitro-and-ex-vivo-susceptibility>.
- <sup>5</sup>*P. falciparum*, strain IPC 4912 was deposited in 2013 with a DHA RSA<sub>0-3h</sub> value of 49.3%.
- <sup>6</sup>Primer sequences and conditions for PCR are available upon request.
- <sup>7</sup>K13-propeller mutation I543T confers artemisinin resistance *in vitro*; for additional information, please refer to Straimer, J., et al. "Drug Resistance. K13-Propeller Mutations Confer Artemisinin Resistance in *Plasmodium falciparum* Clinical Isolates." *Science* 347 (2015): 428-431. PubMed: 25502314.
- <sup>8</sup>Pre-freeze parasitemia was determined after 8 days post infection by microscopic counts of Giemsa-stained blood smears.
- <sup>9</sup>Post-freeze parasitemia was determined after 6 days post infection by microscopic counts of Giemsa-stained blood smears.
- <sup>10</sup>Viability was confirmed by examination of infected erythrocytes for parasitemia at 6 days post infection.
- <sup>11</sup>Atlas, Ronald M. *Handbook of Microbiological Media*. 3rd ed. Ed. Lawrence C. Parks. Boca Raton: CRC Press, 2004, p. 798.


**Figure 1: MRA-1241 MSP2 Sequence**

```
TAAACATTG TCTATTATAA ATTTCTTTAT TTTTGTACC TTTAATATTA AAAATGAAAG TAAATATAGC AACACATTCA
TAAACAATGC TTATAATATG AGTATAAGGA GAAGTATGGC AAATGAAGGT TCTAATACTA CTAGTGTAGG TGCAAATGCT
CCAAATGCTG ATACTATTGC TAGTGGAAAGT CAAAGTAGTA CAAATAGTGC AAGTACTAGT ACTACTAATA ATGGAGAATC
ACAAACTACT ACTCCTACCG CTGCTGATAC CCCTACTGCT ACAAAAAGTA ATTCACCTTC ACCACCCATC ACTACTACAG
AAAGTAATTC ACCTTCACCA CCCATCACTA CTACAGAAAAG TAATTCACCT TCACCACCCA TCACTACTAC AGAAAAGTAAT
TCACCTTCAC CACCCATCAC TACTACAGAA AGTTC AAGTT CTGGCAATGC ACCAAAATAAA ACAGACGGTA AAGGAGAAGA
GAGTGAAAA CAAAATGAAT TAAATGAATC AACTGAAGAA GGACCCAAAG CTCCACAAGA ACCTCAAACG GCAGAAAATG
AAAATCCTGC TGCACCAGAG AATAAAGGTA CAGGACAACA TGGACATATG CATGGTTCTA GAAATAATCA TCCACAAAAT
ACTTCTGATA GTCAAAAAGA ATGTACCGAT GGTAACAAAG AAAACTGTGG AGCAGCAACA TCCCTCTTAA ATAACTCTAG
TAATATTGCT TCAATAAATA AATTTGTTGT TTTAATT
```

**Figure 2: MRA-1241 K13 Sequence**

```
CCATTCATTT GTATCTGGTG AAAAGAAATG ACATGAATTT AGAACTTCGC CATTTTCTCC TCCTGTAATT ATATAAGAAT
CTGACAATGT GGCAGCTCCA AAATTCATTT TTTTCTCTGG TACACCATTT AGAAATTGCC ATCTTTTATT AAATGGTTGA
TATTGTTCAA CGGAATCTAA TATGTTATGT TCATTATCAA TACCTCCAAC AACATATATT TGATTAAGGT AATTAAGAGC
TGCTCCTGAA CTTCTAGCTT CTAATAAGGC ATATGGAAAT TGTTCCCAT TATTCATTTT TTCTTCATAT ACTTCAATAG
AATTTAATCT CTCACCATTA GTTCCACCAA TGACATAAAT TTTATTATCA AAAGCAACAC ACATAGCTGA TGATCTAGGG
GTATTCAAAG GTGCCACCTC TACCCATGCT TTCATACGAT GATCATATGC TTCTACATTC GGTATAATAG AAGAGCCATC
ATATCCCCCA GTACAATAAA TTCTACCATT TGACGTAACA CCACAATTAT TTCTTCTAGG TATATTTAAA TTACTTGAAA
CATACCATAC ATCTCTTAAA CGATCATACA CCTCAGTTTC AAATAAAGCC TTATAATCAT AGTTATTACC ACCAAAAACG
TATAAGAAAT TATTCAATAC AGCACTTCCA AAATAAGCTT TTTTGGTAGA CATAGGTGTA CACATACGCC AGCATTGTTG
ACTAATATCT AATAATTCCA TCGAATTTAA ATATTCTACA CCATCAAATC CACCTATACA AAATACTAAT GGGAAATGGTA
AAAATTTAAT ACCATAAAAT TCTGCTTCTT TCAACAAGGC TTCACTTTCA CTTAAATCTT TTGGTATGGG TATAGTTAAC
GGATTTCTTA AGAAGTTAAG TATAATTCTA AATAACTCAC TATCCCTATC TAAGAATATT CTTCCTTGTT TATCTCTGGT
TACATGATGT CTTCCACTTA ATAATTTCTC TATAAATGAA TCTTTTGTG GTGTTAAGGT ATGTCTAGAT GTTTCAAAA
TAGCTCCACC AACATTAATA TCAATCATAG TTTTCTAGT AATATTGCA TCAACAATT TTTTCTTAT CATTCTCAA
ATTTTTATCT TCTTGATAAT ATTTTCTTT TTCTAAATAT AATACTAATT TAATTTTATC GATTTCTGT AAAAATCTTA
ATCTTTCTTC ATCAAATCGT TTCTTATGTT CTTCTTTTTC TTTTCTTATT TGTTTATAAC CATTAGATAT ATCAATATCT
AATTTCTTTC TTTTCTCATG TAATTTCTGT CTTTCAATAT TTTTACGGTT TTCTAATTCT TTGTACAATC GTACTCTTTC
CATTTCTAGT TCTTTCTTAT CTTTAAATAA TTTTATCTTT TCTCGAATAA AATTCATTTG TGCTTTTTTT AACCAATTAA
TAAATGTAAT TCTTAAATCA CCTACCATAT TTTCAAAATC ACTAGCATCA CTTAATTTCCG TTTCAATAAT TTTCTTTTCA
TAAGTATCAT TTACATTATT TACAGTTGAA AATTTTCTTA AATTGTTTAA TCCAGAATCA TCATTTATAA GATTTGCTGC
ATCTAAAAAA TTCTCTTTTT TGTTGGTATT CATAATTGAT GGAGAATTCA TATTATTATT AATAAGATTA TTAGTTATAT
TATTTGCTGT CAGATTATTA TTATTATTAT TATTATTATG ATTAATATTA TTATTTTCAT TTGTAATAGT ATCTTTTTTT
TTATTTAACA ATTTATTTAA ATATTTATTT CCTATATTAT CTTTACATAT ATTATTAAT GTTCTTGATA AATTACTTGG
TAAAAAATCT TTTTACTAT CAAAGTTCGA ATCTAATACA CTCATATCAA TGGATTCTAA TAGGCTATCT TTAACATTTTC
CATAACTACT ATTATTTAAA AGGAAACTAT TATTTTCCGT TTTCTC
```

Figure 3: Viability of *P. falciparum*, Strain IPC 4912



Date: 09 FEB 2017

Signature:

BEI Resources Authentication

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

